The Safety of GLP-1 Weight Loss Medications

Few medications in recent memory have generated as much public interest — and anxiety — as the GLP-1 receptor agonists used for weight loss. Semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have dominated headlines, social media feeds, and dinner table conversations. With so much information — and misinformation — circulating, patients deserve a clear-eyed look at what the clinical evidence actually tells us.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally in the gut after eating. It signals your brain that you're full, slows gastric emptying, and stimulates insulin release. GLP-1 receptor agonists mimic this hormone, but in a longer-acting form that provides sustained appetite suppression and improved metabolic signaling.

These medications weren't developed overnight. Semaglutide has been used for type 2 diabetes management since 2017, meaning there is now nearly a decade of real-world safety data. Tirzepatide, a dual GIP/GLP-1 receptor agonist, received FDA approval for weight management in 2023 and builds on similar clinical evidence.

What the Clinical Data Shows

The landmark STEP trials (Semaglutide Treatment Effect in People with Obesity) studied semaglutide 2.4mg across thousands of participants. The SELECT trial — a cardiovascular outcomes study with over 17,500 participants — demonstrated not only significant weight loss but a 20% reduction in major adverse cardiovascular events (heart attack, stroke, and cardiovascular death). This is a remarkable finding that reframes these medications from purely cosmetic weight loss aids to treatments with genuine cardiovascular benefit.

Similarly, the SURMOUNT trials for tirzepatide showed average weight loss of 20-25% of body weight, with favorable metabolic improvements in blood sugar, blood pressure, and lipid profiles.

Common Side Effects

The most frequently reported side effects are gastrointestinal:

• Nausea — the most common, affecting up to 40% of patients initially. It is typically mild to moderate and improves significantly as the dose is gradually titrated upward
• Constipation or diarrhea — usually transient and manageable with dietary adjustments
• Decreased appetite — this is largely the intended mechanism of action
• Injection site reactions — minor redness or irritation at the injection site

Most of these side effects are dose-dependent and decrease over time. This is precisely why these medications should be prescribed and managed by a physician who can adjust dosing schedules based on individual tolerability.

Addressing Serious Safety Concerns

Several concerns have circulated in media and online forums that deserve direct attention:

• Thyroid cancer: In rodent studies, GLP-1 agonists were associated with thyroid C-cell tumors. However, this finding has not been replicated in humans, and the mechanism involved (GLP-1 receptor expression on thyroid C-cells) appears to be specific to rodents. That said, these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pancreatitis: While early case reports raised concern, large-scale clinical trials have not shown a statistically significant increase in pancreatitis risk. Patients with a history of pancreatitis should discuss this with their physician
• Gallbladder disease: Rapid weight loss — from any cause — increases the risk of gallstone formation. This is a risk of weight loss itself, not unique to these medications
• Muscle loss: Some patients lose lean body mass along with fat. This can be mitigated with adequate protein intake and resistance exercise — another reason physician supervision is essential

Who Is a Good Candidate?

These medications are FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia). They are not intended as cosmetic weight loss solutions for people at a healthy weight.

Dr. Saad's Medical Approach

At Healing Aesthetics, Dr. Saad approaches weight management as medicine — not a trend. Every patient considering GLP-1 therapy undergoes a comprehensive medical evaluation, including metabolic screening and cardiovascular risk assessment. The medication is prescribed at a carefully titrated dose, with regular follow-up appointments to monitor progress, manage side effects, and adjust the treatment plan.

Equally important is what happens alongside the medication. Dr. Saad emphasizes that GLP-1 agonists are most effective as part of a comprehensive program that includes nutritional guidance, physical activity, and behavioral support. The medication provides the appetite suppression and metabolic shift that makes lifestyle changes sustainable — but it doesn't replace them.

For patients concerned about the aesthetic effects of weight loss, Dr. Saad's unique position as both a weight management physician and aesthetic medicine specialist means he can proactively address concerns like facial volume loss or skin laxity as part of the overall treatment plan.